Reporting of Deaths During Pre-Approval Clinical Trials for Advanced HIV-Infected Populations

Author： Johann-Liang Rosemary   James Andrea N.   Behr Virginia L.   Struble Kimberly   Birnkrant Debra B.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.28, Iss.7, 2005-01, pp. : 559-564

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies

By Caccia Silvio  

Drug Safety, Vol. 32, Iss. 11, 2009-11 ,pp. : 1017-1039

Adis International

Access to resources Recommend Favorite

National review of deaths among HIV-infected adults

By Lucas SB   Curtis H   Johnson MA  

Clinical Medicine, Vol. 8, Iss. 3, 2008-06 ,pp. : 250-252

Royal College Of Physicians

Access to resources Recommend Favorite

Pharmacovigilance during the Pre-Approval Phases: An Evolving Pharmaceutical Industry Model In Response To ICH E2E, CIOMS VI, FDA and EMEA/CHMP Risk-Management Guidelines

By Hartford Craig G.  

Drug Safety, Vol. 29, Iss. 8, 2006-01 ,pp. : 657-673

Adis International

Access to resources Recommend Favorite

ADE reporting in clinical trials lacking

By  

Reactions Weekly, Vol. 1, Iss. 1315, 2010-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women

By Frost C.E.  

Clinical Drug Investigation, Vol. 22, Iss. 2, 2002-01 ,pp. : 125-134

Adis International

Access to resources Recommend Favorite